Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Quarterly Earnings Results

Mirum Pharmaceuticals (NASDAQ:MIRM) posted its earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15, Zacks reports. The company had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 17.40%. The firm’s revenue was up 47.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.30) EPS. Mirum Pharmaceuticals updated its FY 2025 guidance to EPS.

Mirum Pharmaceuticals Stock Down 3.4%

Mirum Pharmaceuticals stock traded down $2.37 during midday trading on Thursday, hitting $67.72. 563,803 shares of the stock were exchanged, compared to its average volume of 554,338. Mirum Pharmaceuticals has a 52-week low of $36.88 and a 52-week high of $78.54. The stock has a market capitalization of $3.40 billion, a price-to-earnings ratio of -78.74 and a beta of 0.75. The business’s 50-day moving average price is $73.22 and its 200-day moving average price is $58.67. The company has a quick ratio of 2.97, a current ratio of 3.13 and a debt-to-equity ratio of 1.21.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,000 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $62.00, for a total value of $2,480,000.00. Following the transaction, the chief executive officer directly owned 138,641 shares in the company, valued at $8,595,742. The trade was a 22.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Laura Brege sold 17,000 shares of the business’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $74.40, for a total transaction of $1,264,800.00. Following the completion of the transaction, the director owned 15,703 shares in the company, valued at approximately $1,168,303.20. The trade was a 51.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 66,578 shares of company stock worth $4,472,824 over the last three months. 14.36% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MIRM. Comerica Bank boosted its stake in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the last quarter. AQR Capital Management LLC boosted its stake in Mirum Pharmaceuticals by 307.3% in the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after acquiring an additional 37,028 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Mirum Pharmaceuticals by 7.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after acquiring an additional 1,720 shares during the last quarter. Caxton Associates LLP purchased a new position in Mirum Pharmaceuticals in the first quarter valued at about $217,000. Finally, Empowered Funds LLC boosted its stake in Mirum Pharmaceuticals by 15.4% in the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after acquiring an additional 5,120 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MIRM. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Wednesday, October 8th. Raymond James Financial restated a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, August 7th. Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, September 26th. Cantor Fitzgerald increased their target price on shares of Mirum Pharmaceuticals from $85.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Mirum Pharmaceuticals from $53.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $83.50.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.